

# Richard M Szydlo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7709046/publications.pdf>

Version: 2024-02-01

220  
papers

10,977  
citations

30070

54  
h-index

32842

100  
g-index

220  
all docs

220  
docs citations

220  
times ranked

9255  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib. <i>Journal of Clinical Oncology</i> , 2010, 28, 2381-2388.	1.6	802
2	Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 3358-3363.	1.6	524
3	Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2012, 30, 232-238.	1.6	449
4	Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. <i>Journal of Clinical Oncology</i> , 1997, 15, 1767-1777.	1.6	440
5	Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in <i>TERC</i> . <i>Nature Genetics</i> , 2004, 36, 447-449.	21.4	425
6	Soluble receptor activator of nuclear factor $\kappa$ B ligand/osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. <i>Blood</i> , 2003, 102, 1064-1069.	1.4	386
7	Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. <i>Lancet</i> , The, 2001, 358, 271-276.	13.7	325
8	Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. <i>Blood</i> , 2011, 117, 3733-3736.	1.4	292
9	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Blood</i> , 2000, 96, 2712-2716.	1.4	243
10	Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. <i>Blood</i> , 2005, 105, 4532-4539.	1.4	228
11	Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. <i>British Journal of Haematology</i> , 1997, 96, 111-116.	2.5	212
12	Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2008, 26, 4806-4813.	1.6	171
13	Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]. <i>Blood</i> , 1993, 82, 2235-2238.	1.4	165
14	Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. <i>Blood</i> , 2005, 106, 2969-2976.	1.4	163
15	Early detection of <i>BCR-ABL</i> transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Blood</i> , 2001, 97, 1560-1565.	1.4	154
16	Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. <i>International Journal of Cancer</i> , 2006, 119, 1728-1731.	5.1	153
17	Serum levels of macrophage inflammatory protein-1 alpha (MIP-1 $\alpha$ ) correlate with the extent of bone disease and survival in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2003, 123, 106-109.	2.5	147
18	Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 1997, 20, 553-560.	2.4	134

#	ARTICLE	IF	CITATIONS
19	Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 119, 5030-5036.	1.4	129
20	Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. <i>Blood</i> , 2006, 107, 205-212.	1.4	127
21	The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. <i>Blood</i> , 2007, 110, 380-383.	1.4	126
22	Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. <i>Blood</i> , 2006, 107, 4171-4176.	1.4	119
23	Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant. <i>Experimental Hematology</i> , 1999, 27, 1477-1486.	0.4	116
24	Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. <i>Blood</i> , 2003, 102, 1217-1223.	1.4	114
25	Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. <i>Haematologica</i> , 2011, 96, 307-314.	3.5	113
26	Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2010, 95, 224-231.	3.5	112
27	Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. <i>Bone Marrow Transplantation</i> , 2015, 50, 209-215.	2.4	108
28	Three decades of transplantation for chronic myeloid leukemia: what have we learned?. <i>Blood</i> , 2011, 117, 755-763.	1.4	103
29	Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A REPORT BY THE EBMT LEUKAEMIA WORKING PARTY. <i>British Journal of Haematology</i> , 1991, 79, 567-574.	2.5	101
30	Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. <i>British Journal of Haematology</i> , 2001, 112, 228-236.	2.5	101
31	The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. <i>Leukemia</i> , 2005, 19, 1969-1976.	7.2	99
32	FOXO1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. <i>Scientific Reports</i> , 2019, 9, 1505.	3.3	96
33	Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. <i>Leukemia</i> , 2005, 19, 507-512.	7.2	94
34	Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). <i>British Journal of Haematology</i> , 2004, 126, 686-689.	2.5	93
35	Unique Localization of Circulating Tumor Cells in Patients With Hepatic Metastases. <i>Journal of Clinical Oncology</i> , 2009, 27, 6160-6165.	1.6	88
36	Bone marrow transplantation for $\beta^0$ -thalassaemia major: the UK experience in two paediatric centres. <i>British Journal of Haematology</i> , 2003, 120, 289-295.	2.5	85

#	ARTICLE	IF	CITATIONS
37	Tartrate-resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma. <i>International Journal of Cancer</i> , 2003, 106, 455-457.	5.1	84
38	Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 443-450.	2.0	84
39	Factors influencing the outcome of bone marrow transplants using unrelated donors. <i>Immunological Reviews</i> , 1997, 157, 153-166.	6.0	82
40	The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 1997, 99, 945-950.	2.5	72
41	Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. <i>Blood</i> , 2002, 99, 2304-2309.	1.4	71
42	Impact of Cyclosporine-A Concentration on the Incidence of Severe Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 28-34.	2.0	70
43	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2167-2171.	2.0	69
44	Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. <i>Blood</i> , 2012, 119, 1838-1843.	1.4	68
45	Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. <i>Bone Marrow Transplantation</i> , 1998, 21, 1055-1061.	2.4	67
46	Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. <i>British Journal of Haematology</i> , 2001, 115, 569-574.	2.5	66
47	Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. <i>Leukemia</i> , 2003, 17, 1448-1453.	7.2	65
48	Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. <i>Blood</i> , 2010, 116, 5497-5500.	1.4	65
49	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. <i>Blood</i> , 2000, 96, 86-90.	1.4	62
50	Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. <i>Leukemia</i> , 2004, 18, 1420-1426.	7.2	61
51	Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 201-206.	1.0	60
52	Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , 2006, 38, 799-805.	2.4	59
53	Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. <i>British Journal of Haematology</i> , 1997, 99, 30-35.	2.5	56
54	Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 74-79.	2.5	56

#	ARTICLE	IF	CITATIONS
55	Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2010, 115, 4018-4020.	1.4	56
56	The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2007, 40, 983-988.	2.4	54
57	CYTOTOXIC T LYMPHOCYTE PRECURSOR FREQUENCY ANALYSES IN BONE MARROW TRANSPLANTATION WITH VOLUNTEER UNRELATED DONORS VALUE IN DONOR SELECTION. <i>Transplantation</i> , 1995, 59, 1302-1307.	1.0	53
58	Paranasal sinusitis following allogeneic bone marrow transplant. <i>Bone Marrow Transplantation</i> , 1997, 19, 55-59.	2.4	53
59	Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 289-294.	2.0	51
60	A study of cytokine gene polymorphisms and protein secretion in renal transplantation. <i>Transplant Immunology</i> , 2001, 8, 237-244.	1.2	49
61	The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status. <i>Journal of Clinical Pathology</i> , 2005, 58, 715-721.	2.0	49
62	Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. <i>Blood</i> , 2009, 113, 4521-4524.	1.4	47
63	Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. <i>Leukemia</i> , 2007, 21, 943-948.	7.2	46
64	Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants. <i>Bone Marrow Transplantation</i> , 2017, 52, 717-725.	2.4	45
65	HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. <i>British Journal of Haematology</i> , 1992, 81, 383-390.	2.5	44
66	CT and MRI Manifestations of Central Nervous System Infection following Allogeneic Bone Marrow Transplantation. <i>Clinical Radiology</i> , 1999, 54, 390-397.	1.1	44
67	IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. <i>Blood</i> , 2004, 103, 717-724.	1.4	43
68	Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. <i>Blood</i> , 2010, 116, 2033-2039.	1.4	43
69	E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2017, 102, e297-e299.	3.5	42
70	Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients. <i>Haematologica</i> , 2020, 105, 2651-2654.	3.5	42
71	Estimation of current leukaemia-free survival following donor lymphocyte infusion therapy for patients with leukaemia who relapse after allografting: application of a multistate model. <i>Statistics in Medicine</i> , 2000, 19, 3005-3016.	1.6	39
72	Summary curves for patients transplanted for chronic myeloid leukaemia salvaged by a donor lymphocyte infusion: the current leukaemia-free survival curve. <i>British Journal of Haematology</i> , 2000, 109, 148-152.	2.5	39

#	ARTICLE	IF	CITATIONS
73	Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. <i>Leukemia and Lymphoma</i> , 2013, 54, 2200-2204.	1.3	39
74	Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]. <i>Blood</i> , 1993, 82, 2235-2238.	1.4	39
75	ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. <i>Blood</i> , 2001, 98, 2879-2880.	1.4	38
76	Capillary zone electrophoresis for haemoglobinopathy diagnosis. <i>Journal of Clinical Pathology</i> , 2013, 66, 29-39.	2.0	38
77	Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2017, 8, 1937.	4.8	38
78	Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1395-1400.	2.4	37
79	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. <i>Haematologica</i> , 2019, 104, 2400-2409.	3.5	37
80	Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. <i>Clinical Nutrition</i> , 2019, 38, 738-744.	5.0	37
81	Anergic T cells exert antigen-independent inhibition of cell-cell interactions via chemokine metabolism. <i>Blood</i> , 2003, 102, 2173-2179.	1.4	36
82	Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. <i>Blood</i> , 2005, 105, 4893-4894.	1.4	36
83	Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. <i>Lancet, The</i> , 2003, 362, 617-619.	13.7	35
84	Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. <i>Haematologica</i> , 2009, 94, 1399-1406.	3.5	34
85	Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia. <i>Science Translational Medicine</i> , 2021, 13, eabf0113.	12.4	32
86	IN VITRO CYTOKINE PROFILES AND THEIR RELEVANCE TO REJECTION FOLLOWING RENAL TRANSPLANTATION. <i>Transplantation</i> , 1995, 60, 703-706.	1.0	30
87	Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding. <i>British Journal of Haematology</i> , 2019, 184, 808-816.	2.5	30
88	Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. <i>British Journal of Haematology</i> , 2018, 182, 418-422.	2.5	28
89	Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. <i>British Journal of Haematology</i> , 2019, 185, 89-92.	2.5	28
90	LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. <i>Bone Marrow Transplantation</i> , 2007, 39, 41-47.	2.4	27

#	ARTICLE	IF	CITATIONS
91	Does a rise in the <i>BCR-ABL1</i> transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?. <i>British Journal of Haematology</i> , 2009, 145, 373-375.	2.5	27
92	Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. <i>British Journal of Haematology</i> , 2022, 196, 566-576.	2.5	27
93	Donor Lymphocyte Infusions (DLI) After Peripheral Blood Stem Cell Transplantation. A Retrospective Analysis of 357 Patients by the Chronic Leukemias Working Party EBMT.. <i>Blood</i> , 2009, 114, 3309-3309.	1.4	26
94	Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. <i>British Journal of Haematology</i> , 2007, 136, 833-836.	2.5	25
95	The Diagnostic Value of CD1d Expression in a Large Cohort of Patients With B-Cell Chronic Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2011, 136, 400-408.	0.7	25
96	EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 235-240.	2.0	25
97	Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. <i>Bone Marrow Transplantation</i> , 2004, 33, 1225-1229.	2.4	24
98	Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. <i>Haematologica</i> , 2010, 95, 922-927.	3.5	24
99	Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. <i>American Journal of Hematology</i> , 2017, 92, 359-366.	4.1	24
100	IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 527-539.	2.5	24
101	Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: Evidence for primary or secondary humoral responses depending on donor immune status. , 1996, 49, 61-65.		21
102	Cytokine secretion in mixed lymphocyte culture: a prognostic indicator of renal allograft rejection in addition to HLA mismatching. <i>Transplant Immunology</i> , 2000, 8, 109-114.	1.2	21
103	Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. <i>Blood</i> , 2008, 112, 2163-2166.	1.4	21
104	Use of thromboelastography to assess the combined role of pregnancy and obesity on coagulation: a prospective study. <i>International Journal of Obstetric Anesthesia</i> , 2013, 22, 113-118.	0.4	21
105	Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. <i>Haematologica</i> , 2011, 96, 1779-1782.	3.5	20
106	Female donors and donors who are lighter than their recipient are less likely to meet the $CD34^+$ cell dose requested for peripheral blood stem cell transplantation. <i>Transfusion</i> , 2014, 54, 2953-2960.	1.6	20
107	A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 705-709.	2.4	18
108	TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 346-355.	2.5	18

#	ARTICLE	IF	CITATIONS
109	Night-time immobilization of the distal interphalangeal joint reduces pain and extension deformity in hand osteoarthritis. <i>Rheumatology</i> , 2014, 53, 1142-1149.	1.9	17
110	Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. <i>Haematologica</i> , 2020, 105, 2639-2646.	3.5	17
111	Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. <i>Blood</i> , 2002, 100, 2673-2673.	1.4	16
112	High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2011, 46, 364-367.	2.4	16
113	Harvests from bone marrow donors who weigh less than their recipients are associated with a significantly increased probability of a suboptimal harvest yield. <i>Transfusion</i> , 2016, 56, 1052-1057.	1.6	16
114	Impaired cellular and humoral immunity is a feature of Diamond-Blackfan anaemia; experience of 107 unselected cases in the United Kingdom. <i>British Journal of Haematology</i> , 2019, 186, 321-326.	2.5	16
115	INTERLEUKIN 3 (IL-3), BUT NOT STEM CELL FACTOR (SCF) INCREASES SELF-RENEWAL BY HUMAN ERYTHROID BURST-FORMING UNITS (BFU-E) IN VITRO. <i>Cytokine</i> , 1998, 10, 49-54.	3.2	15
116	Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. <i>Blood</i> , 2022, 139, 1939-1953.	1.4	15
117	CYTOTOXIC T LYMPHOCYTE PRECURSOR FREQUENCY ANALYSES IN BONE MARROW TRANSPLANTATION WITH VOLUNTEER UNRELATED DONORS VALUE IN DONOR SELECTION. <i>Transplantation</i> , 1995, 59, 1302-1307.	1.0	14
118	Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1599-1601.	2.4	14
119	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 684659.	3.9	14
120	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. <i>Immunotherapy Advances</i> , 2021, 1, .	3.0	14
121	High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience. <i>British Journal of Haematology</i> , 2000, 108, 769-777.	2.5	13
122	Glue versus mechanical mesh fixation in laparoscopic inguinal hernia repair: meta-analysis and trial sequential analysis of randomized clinical trials. <i>British Journal of Surgery</i> , 2021, 108, 14-23.	0.3	13
123	Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy. <i>Blood</i> , 2012, 120, 5087-5088.	1.4	12
124	Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1324-1328.	2.4	11
125	Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 350-356.	2.0	11
126	Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia. , 2000, 27, 278-284.		10



#	ARTICLE	IF	CITATIONS
127	The use of a national transplant registry to benchmark transplant outcome for patients undergoing autologous and allogeneic stem cell transplantation in the United Kingdom and Ireland. <i>British Journal of Haematology</i> , 2004, 124, 499-503.	2.5	10
128	Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2007, 31, 1433-1436.	0.8	10
129	Duplex quantitative PCR for molecular monitoring of <i>BCR-ABL1</i> associated hematological malignancies. <i>American Journal of Hematology</i> , 2011, 86, 313-315.	4.1	10
130	Mild chronic graft-versus-host disease may alleviate poor prognosis associated with <i>FLT3</i> internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study. <i>European Journal of Haematology</i> , 2016, 96, 236-244.	2.2	10
131	MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. <i>Haematologica</i> , 2019, 104, 2206-2214.	3.5	10
132	Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. <i>Leukemia</i> , 2020, 34, 667-670.	7.2	10
133	Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.. <i>Blood</i> , 2009, 114, 3290-3290.	1.4	10
134	Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons. <i>British Journal of Haematology</i> , 2003, 122, 424-429.	2.5	9
135	LACE conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. <i>Hematological Oncology</i> , 2011, 29, 75-80.	1.7	9
136	Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose. <i>The Hematology Journal</i> , 2001, 2, 265-272.	1.4	9
137	Prognostic Factors for Survival post Surgery for Patients with Gastrointestinal Stromal Tumors. <i>European Surgical Research</i> , 2012, 48, 3-9.	1.3	8
138	Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. <i>British Journal of Haematology</i> , 2012, 157, 125-127.	2.5	8
139	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. <i>Bone Marrow Transplantation</i> , 2020, 55, 1975-1984.	2.4	8
140	Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm. <i>Leukemia</i> , 2021, 35, 2424-2430.	7.2	8
141	Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK: a multicentre observational study. <i>British Journal of Haematology</i> , 2022, 196, 79-94.	2.5	8
142	Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2019, 134, 26-26.	1.4	8
143	Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia. <i>Bone Marrow Transplantation</i> , 2000, 25, 143-146.	2.4	7
144	A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation. <i>Genome Medicine</i> , 2015, 7, 128.	8.2	7

#	ARTICLE	IF	CITATIONS
145	Better HLA Matching as Revealed Only by Next Generation Sequencing Technology Results in Superior Overall Survival Post-Allogeneic Haematopoietic Cell Transplantation with Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S63-S64.	2.0	7
146	C-Reactive Protein on Admission Predicts Transplant-Related Mortality in Recipients of Allogeneic Stem Cell Transplant.. <i>Blood</i> , 2007, 110, 3005-3005.	1.4	7
147	Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT. <i>Annals of Transplantation</i> , 2011, 16, 47-54.	0.9	7
148	Assessment of quantitative polymerase chain reaction for <i>BCR-ABL1</i> transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?. <i>British Journal of Haematology</i> , 2022, 197, 52-62.	2.5	7
149	Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2006, 37, 937-943.	2.4	6
150	Sign of the Zodiac as a Predictor of Survival for Recipients of an Allogeneic Stem Cell Transplant for Chronic Myeloid Leukaemia (CML): An Artificial Association. <i>Transplantation Proceedings</i> , 2010, 42, 3312-3315.	0.6	6
151	C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early and long-term mortality. <i>British Journal of Haematology</i> , 2018, 180, 889-892.	2.5	6
152	Diagnostic application of transcripts associated with antibody-mediated rejection in kidney transplant biopsies. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1576-1584.	0.7	6
153	High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2690-2696.	2.4	6
154	Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.. <i>Blood</i> , 2010, 116, 3414-3414.	1.4	6
155	Abnormal Patterns of Immunoglobulin Heavy Chain Gene DNA Fingerprinting During Chronic Phase Chronic Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1999, 32, 299-307.	1.3	5
156	Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab. <i>Transplant Immunology</i> , 2007, 18, 179-185.	1.2	5
157	Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk. <i>Journal of Clinical Pathology</i> , 2011, 64, 829-831.	2.0	5
158	The finer points of writing and refereeing scientific articles. <i>British Journal of Haematology</i> , 2016, 172, 350-359.	2.5	5
159	A novel Haematology Frailty (HOF) score tool predicts survival in over 80s with Multiple Myeloma. <i>British Journal of Haematology</i> , 2019, 187, e72-e75.	2.5	4
160	Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients. <i>Blood</i> , 2018, 132, 3007-3007.	1.4	4
161	Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies. <i>Blood</i> , 2008, 112, 2378-2378.	1.4	4
162	Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 3392-3392.	1.4	4

#	ARTICLE	IF	CITATIONS
163	The relationship between the Physicochemical properties of pyrethroid insecticides and their speed of neurotoxic action. <i>Pest Management Science</i> , 1985, 16, 673-683.	0.4	3
164	Surviving survival analysis. <i>Bone Marrow Transplantation</i> , 2001, 28, 907-907.	2.4	3
165	Specific patterns of chromosomal gains and losses associate with t(3;14), t(8;14), and t(14;18) in diffuse large B-cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2009, 194, 48-52.	1.0	3
166	Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma. <i>Hematological Oncology</i> , 2012, 30, 214-215.	1.7	3
167	Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib. <i>Blood</i> , 2011, 118, 1680-1680.	1.4	3
168	Cancer-Selective Targeting of the NF- $\kappa$ B Survival Pathway in Multiple Myeloma with the GADD45 <sup>2</sup> /MKK7 Inhibitor, DTP3. <i>Blood</i> , 2015, 126, 868-868.	1.4	3
169	Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Matched and Single Antigen Mismatched Unrelated Bone Marrow Transplantation in Haemoglobinopathies Is Feasible and Leads to Early and Sustained Engraftment with No Long-Term Toxicity or GvHD. <i>Blood</i> , 2016, 128, 2468-2468.	1.4	3
170	Phenotypic Characterization of Normal and CML CD34 <sup>+</sup> Positive Cells: Only the Most Primitive CML Progenitors Include Ph-neg Cells. <i>Leukemia and Lymphoma</i> , 1993, 11, 51-61.	1.3	2
171	Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1729-1735.	2.0	2
172	Impact of HLA Class I and Class II DNA High-Resolution HLA Typing on Outcome in Adult Unrelated Stem Cell Transplantation after In Vivo T-Cell Depletion with CAMPATH 1H: A Single Centre Experience in 100 Patients.. <i>Blood</i> , 2005, 106, 1804-1804.	1.4	2
173	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. <i>Blood</i> , 2000, 96, 86-90.	1.4	2
174	Survival after bone-marrow transplantation. <i>Lancet, The</i> , 2002, 359, 888-889.	13.7	1
175	Reply to Z.S. Lalmahomed et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e290-e290.	1.6	1
176	Impact of Hemochromatosis Gene (HFE) Polymorphisms and Iron Overload on Outcome of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S210.	2.0	1
177	Night-time splinting of the distal interphalangeal joint reduces pain and improves extension at the joint: results from the splint-OA study. <i>Osteoarthritis and Cartilage</i> , 2013, 21, S25-S26.	1.3	1
178	A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e270-e271.	2.0	1
179	Absence of damaging effects of stem cell donation in unrelated donors assessed by FISH and gene variance screening. <i>Bone Marrow Transplantation</i> , 2020, 55, 1290-1296.	2.4	1
180	High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. <i>Blood</i> , 2010, 116, 2539-2539.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Blood</i> , 2016, 128, 2226-2226.	1.4	1
182	Haemopoietic Stem Cell Transplantation for Diamond Blackfan Anaemia Leads to Early and Sustained Engraftment with Good Long-Term Outcomes, but Has an Increased Risk of Gut Toxicity and Lung GvHD. <i>Blood</i> , 2016, 128, 2679-2679.	1.4	1
183	The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions. <i>Blood</i> , 2016, 128, 5987-5987.	1.4	1
184	The effects of the first in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in estrogen receptor positive early breast cancer: Results of the perioperative IPET study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23140-e23140.	1.6	1
185	Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs. <i>Blood</i> , 2010, 116, 2274-2274.	1.4	1
186	Feto-maternal haemorrhage does not account for the differences in cord blood volume obtained from Black and Asian versus Caucasoid donors. <i>British Journal of Haematology</i> , 2010, 148, 951-953.	2.5	0
187	Risk Score Predicts Outcome of Second Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S155.	2.0	0
188	Effect of direct-acting oral anticoagulants (DOACs) on bleeding and blood product usage in cardiac surgery compared to warfarin and controls. <i>British Journal of Haematology</i> , 2020, 190, 284-293.	2.5	0
189	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Blood</i> , 2000, 96, 2712-2716.	1.4	0
190	Long Term Survival Analysis after High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation for Treatment of AL Amyloidosis: A Single Centre Experience.. <i>Blood</i> , 2005, 106, 5503-5503.	1.4	0
191	Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival.. <i>Blood</i> , 2005, 106, 1984-1984.	1.4	0
192	Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT).. <i>Blood</i> , 2007, 110, 464-464.	1.4	0
193	Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.. <i>Blood</i> , 2008, 112, 970-970.	1.4	0
194	Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT. <i>Blood</i> , 2008, 112, 4301-4301.	1.4	0
195	Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2008, 112, 3319-3319.	1.4	0
196	BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.. <i>Blood</i> , 2009, 114, 3248-3248.	1.4	0
197	The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure.. <i>Blood</i> , 2009, 114, 2147-2147.	1.4	0
198	Presence of the Killer Immunoglobulin-Like Gene KIR3DS1 Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma.. <i>Blood</i> , 2009, 114, 2840-2840.	1.4	0

#	ARTICLE	IF	CITATIONS
199	2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection. <i>Blood</i> , 2010, 116, 677-677.	1.4	0
200	Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 3515-3515.	1.4	0
201	Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 3488-3488.	1.4	0
202	The Diagnostic Value of CD1d Expression In Leukemic B-Chronic Lymphoproliferative Disorders (B-CLPDs). <i>Blood</i> , 2010, 116, 3576-3576.	1.4	0
203	Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations,. <i>Blood</i> , 2011, 118, 4052-4052.	1.4	0
204	Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,. <i>Blood</i> , 2011, 118, 3753-3753.	1.4	0
205	Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1945-1945.	1.4	0
206	Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.. <i>Blood</i> , 2012, 120, 2789-2789.	1.4	0
207	A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.. <i>Blood</i> , 2012, 120, 2555-2555.	1.4	0
208	Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads To High Rates Of Long-Term Engraftment and Low Toxicity Enabling The Use Of Mismatched and Unrelated Donors For Transplantation In Haemoglobinopathies. <i>Blood</i> , 2013, 122, 2041-2041.	1.4	0
209	The Depth Of "Complete"™ Molecular Response Predicts Molecular Relapse In Chronic Myeloid Leukaemia Patients On Tyrosine Kinase Inhibitor Therapy. <i>Blood</i> , 2013, 122, 5201-5201.	1.4	0
210	Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8592-8592.	1.6	0
211	Clinical Outcome Following Change of Tyrosine Kinase Inhibitor (TKI) According to the Detection of an ABL Kinase Mutation. <i>Blood</i> , 2014, 124, 4557-4557.	1.4	0
212	Patient Age Predicts the Delay before Survivors of Cancer Utilise Their Cryopreserved Sperm for Assisted Reproductive Technology. <i>Blood</i> , 2015, 126, 4481-4481.	1.4	0
213	Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3411-3411.	1.4	0
214	Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in $\beta^2$ Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD. <i>Blood</i> , 2016, 128, 1283-1283.	1.4	0
215	Complete Remission with Incomplete Count Recovery (CRI) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk. <i>Blood</i> , 2018, 132, 4650-4650.	1.4	0
216	Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 204-204.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors. <i>Blood</i> , 2019, 134, 3249-3249.	1.4	0
218	Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia. <i>Blood</i> , 2020, 136, 1-2.	1.4	0
219	Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 183.e1-183.e8.	1.2	0
220	Impact of aspirin on bleeding and blood product usage in off-pump and on-pump coronary artery bypass graft surgery. <i>EJHaem</i> , 0, , .	1.0	0